AYTU BIOPHARMA, INC (AYTU) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US0547548588

Price
1.98 USD
Market cap
21.52 m USD
P/E (2026)
–
P/S (2026)
0.37
Dividend yield
0.00 %
Net margin
-24.76 %
Return on equity (ROE)
-40.40 %
Return on assets (ROA)
-13.57 %

AYTU BIOPHARMA, INC financials

Fiscal year20252026
Revenue66.38 m USD57.57 m USD
Gross profit45.83 m USD36.82 m USD
Operating income-7.83 m USD-8.32 m USD
EBIT-9.42 m USD-12.34 m USD
Net income-13.56 m USD-14.25 m USD

Full history since 2007, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About AYTU BIOPHARMA, INC

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.